Taylor Hoffman Wealth Management trimmed its stake in Pfizer Inc. (NYSE:PFE) by 9.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 19,358 shares of the biopharmaceutical company’s stock after selling 1,950 shares during the period. Taylor Hoffman Wealth Management’s holdings in Pfizer were worth $696,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of PFE. Weybosset Research & Management LLC boosted its stake in shares of Pfizer by 2.0% in the 2nd quarter. Weybosset Research & Management LLC now owns 12,847 shares of the biopharmaceutical company’s stock valued at $557,000 after buying an additional 250 shares during the period. Financial Gravity Wealth Inc. lifted its stake in Pfizer by 33.2% during the second quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 257 shares during the last quarter. Intl Fcstone Inc. lifted its stake in Pfizer by 2.4% during the second quarter. Intl Fcstone Inc. now owns 11,140 shares of the biopharmaceutical company’s stock worth $483,000 after purchasing an additional 261 shares during the last quarter. Lee Financial Co lifted its stake in Pfizer by 6.2% during the second quarter. Lee Financial Co now owns 4,569 shares of the biopharmaceutical company’s stock worth $198,000 after purchasing an additional 265 shares during the last quarter. Finally, Sheets Smith Wealth Management lifted its stake in Pfizer by 0.6% in the third quarter. Sheets Smith Wealth Management now owns 47,993 shares of the biopharmaceutical company’s stock valued at $1,724,000 after buying an additional 272 shares during the last quarter. 71.52% of the stock is owned by hedge funds and other institutional investors.
PFE stock traded up $0.14 on Friday, reaching $37.05. 24,924,227 shares of the company’s stock were exchanged, compared to its average volume of 23,366,957. The stock has a fifty day moving average of $36.62 and a 200-day moving average of $39.26. Pfizer Inc. has a twelve month low of $33.97 and a twelve month high of $46.47. The firm has a market cap of $207.30 billion, a PE ratio of 12.35, a P/E/G ratio of 2.11 and a beta of 0.67. The company has a quick ratio of 1.21, a current ratio of 1.47 and a debt-to-equity ratio of 0.60.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.13. The firm had revenue of $12.68 billion for the quarter, compared to analyst estimates of $12.37 billion. Pfizer had a return on equity of 28.61% and a net margin of 30.57%. Pfizer’s quarterly revenue was down 4.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.78 earnings per share. On average, equities research analysts predict that Pfizer Inc. will post 2.96 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.36 per share. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a yield of 3.89%. Pfizer’s payout ratio is 48.00%.
In other news, Director Scott Gottlieb bought 3,000 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were bought at an average cost of $34.72 per share, for a total transaction of $104,160.00. Following the completion of the transaction, the director now owns 3,000 shares in the company, valued at $104,160. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Pfizer Inc bought 50,000 shares of the firm’s stock in a transaction on Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $900,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by insiders.
A number of equities research analysts have weighed in on the company. UBS Group reiterated a “neutral” rating and issued a $43.00 price objective on shares of Pfizer in a research note on Monday, August 5th. DZ Bank raised Pfizer from a “sell” rating to a “hold” rating and set a $36.00 target price on the stock in a report on Wednesday, August 28th. Credit Suisse Group reissued a “hold” rating and issued a $41.30 target price on shares of Pfizer in a report on Wednesday. Bank of America began coverage on Pfizer in a report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 target price on the stock. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Pfizer in a report on Tuesday, October 29th. Nine research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Pfizer has an average rating of “Hold” and a consensus target price of $44.02.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: Market Perform
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.